跳至主要内容
临床试验/NCT00652392
NCT00652392已完成3 期

A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM

AstraZeneca0 个研究点目标入组 750 人开始时间: 2003年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
750
主要终点
Change in evening PEF

研究概览

简要总结

The purpose of this study is to compare a dose of Symbicort taken once daily with other dosage regimens of Symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of asthma and baseline lung function tests as determined by the protocol
  • Required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol

排除标准

  • Severe asthma
  • Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers

研究组 & 干预措施

1

Experimental

干预措施: budesonide/formoterol (Drug)

2

Placebo Comparator

干预措施: budesonide and placebo (Drug)

结局指标

主要结局

Change in evening PEF

时间窗: Daily throughout the 12 week treatment period

次要结局

  • Lung function, asthma symptoms, use of rescue medication and parent/caregiver/physician reported outcomes(Daily throughout the 12 week treatment period)
  • Health-related quality of life(4 assessments within 12 week treatment period)
  • Routine safety assessments(4 assessments within 12 week treatment period)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验